Research & Development
European Commission clears first pertuzumab biosimilar in Europe
29 April 2026 - China-based biopharmaceutical company Shanghai Henlius Biotech Inc (HK:2696) and US healthcare company Organon (NYSE:OGN) announced on Wednesday that the European Commission has approv...
Vanda Pharmaceuticals reports publication of imsidolimab phase III findings in NEJM Evidence
29 April 2026 - US biopharmaceutical company Vanda Pharmaceuticals Inc (Nasdaq:VNDA) announced on Tuesday the publication of an original research article titled 'Efficacy and Safety of Imsidolima...
C-Ray Therapeutics' Copper-64 (Cu-64) Type II DMF gains FDA acceptance
29 April 2026 - Chinese biopharmaceutical company C-Ray Therapeutics (Chengdu) Co Ltd announced on Tuesday that its Type II Drug Master File (DMF) for COPPER [64Cu] CHLORIDE FOR RADIOLABELLING has bee...
GSK hepatitis B therapy bepirovirsen gains FDA priority review and breakthrough designation
28 April 2026 - Biopharmaceutical company GSK plc (LON:GSK) (NYSE:GSK) announced on Tuesday that the US Food and Drug Administration (FDA) has accepted its New Drug Application for bepirovirsen for pr...
Johnson & Johnson IMAAVY (nipocalimab-aahu) granted FDA Priority Review as potential treatment for wAIHA
28 April 2026 - US healthcare company Johnson & Johnson (J&J) (NYSE:JNJ) announced on Monday that the US Food and Drug Administration (FDA) has granted Priority Review to the supplemental Biol...
Xcovery and EVERSANA partner for US commmercialisation of lung cancer drug Ensacove
28 April 2026 - US pharmaceutical company Xcovery Holdings Inc announced on Monday an agreement with EVERSANA, a provider of commercialisation services to the global life sciences industry, to support...